Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 8/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 5/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.31 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160616 | 0.87 | ITGB1 (0.36) | ITGB1ITGA4FFAR2C5AR1 | |
| SCHEMBL5161828 | 0.85 | ITGB1 (0.35) | ITGB1ITGA4FFAR2C5AR1 | |
| SCHEMBL5158473 | 0.84 | ITGB1 (0.42) | ITGB1ITGA4 | |
| SCHEMBL5160549 | 0.82 | FFAR2 (0.35) | ITGB1ITGA4ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14371609 | 0.80 | ITGA4 (0.40) | ITGB1ITGA4ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5160740 | 0.79 | ITGB1 (0.42) | ITGB1ITGA4ALDH1A1 | |
| SCHEMBL5160838 | 0.78 | ITGB1 (0.49) | ITGB1ITGA4 | |
| SCHEMBL5160614 | 0.77 | ITGA4 (0.44) | ITGB1ITGA4C5AR1 | |
| SCHEMBL5407542 | 0.76 | ITGA4 (0.36) | ITGB1ITGA4FFAR2 | |
| SCHEMBL5160790 | 0.75 | ITGB1 (0.50) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ITGB1 9/4885ITGA4 3/4885ALDH1A1 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.